Pivotal phase III trial included over 1000 advanced
first-line patients enrolled in total across squamous and non-squamous histologies

ABRAXANE phase 3 trial design for non-small cell lung cancer
  • Secondary end points: Progression-free survival (PFS) and overall survival (OS)2
  • Treatment administered until disease progression or development of unacceptable toxicity
ECOG PS=Eastern Cooperative Oncology Group performance status.

Pivotal phase III trial included over 1000 advanced
first-line patients enrolled in total across squamous and non-squamous histologies

ABRAXANE phase 3 trial design for non-small cell lung cancer
  • Secondary end points: Progression-free survival (PFS) and overall survival (OS)2
  • Treatment administered until disease progression or development of unacceptable toxicity
ECOG PS=Eastern Cooperative Oncology Group performance status.

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.